浏览全部资源
扫码关注微信
1.安徽中医药大学 研究生院,合肥 230038
2.安徽中医药大学 第一附属医院,合肥 230031
3.安徽中医药大学 第二附属医院,合肥 230061
杨琪琪,在读博士,从事针灸临床及机制研究,E-mail:821920266@qq.com
李飞,主任医师、副教授,从事针灸临床应用及机制研究,Tel:0551-62668820,E-mail:316029622@qq.com
收稿日期:2023-03-23,
网络出版日期:2023-05-06,
纸质出版日期:2023-07-05
移动端阅览
杨琪琪,马守亮,姜天鑫等.基于《新型冠状病毒感染诊疗方案(试行第十版)》探讨中药联合隔物灸贴治疗新型冠状病毒感染恢复期患者方案优化的临床疗效[J].中国实验方剂学杂志,2023,29(13):96-103.
YANG Qiqi,MA Shouliang,JIANG Tianxin,et al.Clinical Efficacy of Chinese Medicine Combined with Indirect Moxibustion Plaster on COVID-19 Patients During Recovery Period Based on COVID-19 Diagnosis and Treatment Protocol(Tenth Edition)[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(13):96-103.
杨琪琪,马守亮,姜天鑫等.基于《新型冠状病毒感染诊疗方案(试行第十版)》探讨中药联合隔物灸贴治疗新型冠状病毒感染恢复期患者方案优化的临床疗效[J].中国实验方剂学杂志,2023,29(13):96-103. DOI: 10.13422/j.cnki.syfjx.20222090.
YANG Qiqi,MA Shouliang,JIANG Tianxin,et al.Clinical Efficacy of Chinese Medicine Combined with Indirect Moxibustion Plaster on COVID-19 Patients During Recovery Period Based on COVID-19 Diagnosis and Treatment Protocol(Tenth Edition)[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(13):96-103. DOI: 10.13422/j.cnki.syfjx.20222090.
目的
2
观察中药联合隔物灸贴治疗新型冠状病毒(以下简称新冠)感染恢复期患者的临床疗效。
方法
2
将90例新冠感染恢复期患者随机分为中药组、隔物灸贴组、中药联合隔物灸贴组(联合组),每组各30例。基于《新型冠状病毒感染诊疗方案(试行第十版)》(《方案》)的恢复期中医药方案进行治疗,中药组予以辨证中药口服治疗,每日1剂,日服2次;隔物灸贴组予以足三里、脾俞、大椎、肺俞、孔最、天突等穴灸贴治疗,每日1次,每次贴敷40 min;联合组予以中药联合隔物灸贴治疗,疗程2周。分别于治疗前后观察各组中医症状评分、肺部计算机断层扫描术(CT)评分、圣乔治呼吸问卷(SGRQ)评分、血常规指标[白细胞计数(WBC)、中性粒细胞计数(NEUT)、淋巴细胞计数(LYM)]、炎症指标[C反应蛋白(CRP)、血清铁蛋白、白细胞介素-6(IL-6)]水平,并评定各组临床疗效。
结果
2
与本组治疗前比较,治疗后各组患者中医症状总分及单项评分、肺部CT评分、SGRQ评分、CRP、IL-6、铁蛋白水平均明显降低(
P
<
0.05),WBC、LYM明显升高(
P
<
0.05),NEUT水平较治疗前差异无统计学意义。与中药组和隔物灸贴组治疗后比较,联合组患者上述指标均优于中药组与隔物灸贴组,差异具有统计学意义(
P
<
0.05)。治疗后联合组患者愈显率为76.7%(23/30),中药组患者愈显率为50.0%(15/30),隔物灸贴组患者愈显率为46.7%(14/30),联合组患者愈显率明显高于中药组(
χ
2
=4.593,
P
<
0.05)和隔物灸贴组(
χ
2
=5.711,
P
<
0.05),差异具有统计学意义。联合组患者总有效率为96.7%(29/30),中药组患者总有效率为93.3%(28/30),隔物灸贴组患者总有效率为86.7%(26/30),联合组患者总有效率高于中药组和隔物灸贴组,但差异无统计学意义。
结论
2
中药联合隔物灸贴治疗可有效改善新冠感染恢复期患者临床症状,促进肺部炎症、血常规、炎症指标改善,提高生活质量,较单纯中药治疗和隔物灸贴治疗更具优势。
Objective
2
To observe the clinical efficacy of Chinese medicine combined with indirect moxibustion plaster on corona virus disease 2019 (COVID-19) patients during recovery period.
Method
2
Ninety patients of COVID-19 during the recovery period were randomly divided into a Chinese medicine group, an indirect moxibustion plaster group, and a combination group,with 30 cases in each group. According to the 10th edition of COVID-19 Diagnosis and Treatment Protocol,patients in the Chinese medicine group received oral Chinese medicine based on syndrome differentiation,one dose per day, twice a day. Patients in the indirect moxibustion plaster group were treated with indirect moxibustion plaster at Zusanli (ST 36), Pishu (BL 20), Dazhui (GV 14), Feishu (BL 13), Kongzui (LU 6), and Tiantu (CV 22),once a day,40 min each time. Patients in the combination group were treated with Chinese medicine combined with indirect moxibustion plaster. Treatment lasted two weeks. Before and after treatment,the traditional Chinese medicine (TCM) symptom score,pulmonary computed tomography (CT) score,St. George's Respiratory Questionnaire (SGRQ) score,blood routine indexes [white blood cell count (WBC),neutrophil count (NEUT),and lymphocyte count (LYM)], and inflammatory indexes [C-reactive protein (CRP),serum ferritin, and interleukin-6 (IL-6)] were observed in the three groups. The clinical efficacy was evaluated.
Result
2
After treatment,the scores of TCM symptoms,pulmonary CT, and SGRQ,CRP,IL-6,and ferritin in the three groups decreased(
P
<
0.05),while WBC and LYM increased(
P
<
0.05), but there was no significant difference in NEUT. The above indexes in the combination group were better than those in the other two groups(
P
<
0.05). After treatment, the cured and markedly effective rate was 76.7% (23/30) in the combination group, 50.0% (15/30) in the Chinese medicine group, and 46.7% (14/30) in the indirect moxibustion plaster group. The cured and markedly effective rate of the combination group was significantly higher than that of the Chinese medicine group (
χ
2
=4.593,
P
<
0.05) and the indirect moxibustion plaster group (
χ
2
=5.711,
P
<
0.05). The total effective rate was 96.7 % (29/30) in the combination group, 93.3% (28/30) in the Chinese medicine group, and 86.7% (26/30) in the indirect moxibustion plaster group. The total effective rate of the combination group was higher than that of the Chinese medicine group and the indirect moxibustion plaster group, but the differences were not statistically significant.
Conclusion
2
Chinese medicine combined with indirect moxibustion plaster can effectively improve the clinical symptoms,promote pulmonary inflammation,blood routine indexes, and inflammatory indexes, and improve the quality of life of COVID-19 patients during the recovery period,which is more advantageous than Chinese medicine alone or indirect moxibustion plaster.
高瞻 , 骆长永 , 郝文翠 , 等 . 新型冠状病毒奥密克戎感染发热期的中医药治疗 [J]. 北京中医药 , 2023 , 42 ( 1 ): 24 - 26 .
罗志辉 , 王昆秀 , 张艳琳 , 等 . “标本配穴”毫火针治疗新型冠状病毒肺炎恢复期后遗症33例疗效观察 [J]. 中国针灸 , 2022 , 42 ( 7 ): 760 - 764 .
RAGHEB J , MCKINNEY A , ZIERAU M , et al . Delirium and neuropsychological outcomes in critically ill patients with COVID19:A cohort study [J]. BMJ Open , 2021 , 11 ( 9 ): e50045
陈蕾 , 谢俊刚 . 《新型冠状病毒感染诊疗方案(试行第十版)》解读 [J]. 医药导报 , 2023 , 42 ( 3 ): 308 - 310 .
湖北省健康管理学会 , 中华医学会健康管理学分会 . 新型冠状病毒感染恢复期健康管理专家共识 [J]. 健康研究 , 2022 , 42 ( 6 ): 601 - 611 .
王成祥 , 冯淬灵 , 于会勇 , 等 . 新型冠状病毒感染恢复期中医药综合干预方案(试行第二版) [J]. 北京中医药 , 2023 , 42 ( 1 ): 40 - 43 .
詹志来 , 刘佳 , 杨伟 , 等 . 基于病例分析的中医药治疗新型冠状病毒肺炎疗效评价标准的探索研究 [J]. 中医杂志 , 2020 , 61 ( 12 ): 1013 - 1023 .
占丰富 , 曾惠清 , 黄茂宏 , 等 . 年龄和CT评分预测新冠肺炎住院患者的死亡风险:基于A-DROP评分 [J]. 中国医药导刊 , 2022 , 24 ( 4 ): 366 - 374 .
孟现玲 , 何玉廷 , 毛若琳 , 等 . 圣乔治呼吸问卷、CAT及mMRC评分在慢性阻塞性肺病中的应用 [J]. 复旦学报:医学版 , 2022 , 49 ( 6 ): 862 - 868,876 .
国家中医药管理局 . 中医病证诊断疗效标准 [M]. 北京 : 中国医药科技出版社 , 2012 : 214 .
任星 , 杨静 , 张菀桐 , 等 . 基于网络药理学探讨新冠肺炎初期用药清肺排毒汤的作用机制 [J]. 世界中医药 , 2021 , 16 ( 19 ): 2845 - 2850 .
李赛娟 , 苏娟 , 靳灿 , 等 . 中药抗冠状病毒的作用机制及临床应用研究进展 [J]. 中草药 , 2023 , 54 ( 1 ): 334 - 345 .
罗志辉 , 王昆秀 , 张艳琳 等 . 回顾性分析三消饮加减方治疗轻型/普通型新型冠状病毒肺炎患者的临床疗效 [J]. 中国实验方剂学杂志 , 2022 , 28 ( 1 ): 150 - 156 .
李佳霖 , 陆珊 , 范啸天 , 等 . 基于网络药理学和分子对接的京制咳嗽痰喘丸治疗新冠肺炎机制研究 [J]. 世界中医药 , 2021 , 16 ( 23 ): 3478 - 3483 .
李玉丽 , 谭周进 , 袁振仪 . 中医"三药三方"防治新型冠状病毒肺炎研究进展 [J]. 时珍国医国药 , 2021 , 32 ( 5 ): 1251 - 1253 .
魏雅雯 , 李谨彤 , 任夏 , 等 . 基于数据驱动分析的抗病毒中药分布规律 [J]. 中草药 , 2021 , 52 ( 16 ): 4959 - 4972 .
孙宪泓 , 史锁芳 , 王博寒 , 等 . 中医药综合康复方案治疗新型冠状病毒肺炎恢复期不同证型患者的临床研究 [J]. 中华中医药杂志 , 2022 , 37 ( 7 ): 4181 - 4185 .
丁波 , 刘令令 , 段飞 . 基于网络药理学和分子对接探讨新型冠状病毒肺炎肺脾气虚证恢复期复方的作用机制 [J]. 中医研究 , 2022 , 35 ( 9 ): 63 - 69 .
医政医管局 . 《新型冠状病毒肺炎诊疗方案(试行第六版)》解读 [J]. 中国临床医生杂志 , 2020 , 48 ( 3 ): 377 - 378 .
吕睿冰 , 王文菊 , 李欣 . 连花清瘟颗粒联合西药常规疗法治疗新型冠状病毒肺炎疑似病例63例临床观察 [J]. 中医杂志 , 2020 , 61 ( 8 ): 655 - 659 .
陈霞 , 黄伟 , 刘保延 , 等 . 艾灸疗法防治新型冠状病毒肺炎:非接触式诊疗模式构建与应用 [J]. 中国针灸 , 2020 , 40 ( 10 ): 1027 - 1033 .
WANG Y , JIANG Q , XIA Y Y , et al . Involvement of α7nAChR in electroacupuncture relieving neuropathic pain in the spinal cord of rat with spared nerve injury [J]. Brain Res Bull , 2018 , 137 : 257 - 264 .
郑婕 , 罗嘉欣 . 穴位贴敷防治新型冠状病毒肺炎作用机制探讨 [J]. 中医学报 , 2021 , 36 ( 3 ): 461 - 464 .
区静怡 , 谭明凯 , 陈星 , 等 . 炎症指标及血常规在新型冠状病毒肺炎患者病程中的水平变化及应用价值 [J]. 检验医学与临床 , 2021 , 18 ( 6 ): 733 - 737 .
马春成 , 李叶枚 , 伍劲华 . 新型冠状病毒恢复期患者应用加减五叶芦根汤联合艾灸调适法临床疗效观察 [J]. 亚太传统医药 , 2021 , 17 ( 12 ): 113 - 117 .
0
浏览量
39
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构